The 160 basis point gross margin expansion over eight quarters indicates that the mix shift toward specialty pharmaceuticals and manufacturer services is gradually lifting profitability, even though operating margin remains razor-thin at 1.3%. Net margin of 0.9% in 2026Q3 underscores the inherent low-margin nature of drug distribution, where even small improvements in gross margin can have outsized effects on net income. Investors should monitor whether this margin expansion is sustainable as biosimilar penetration accelerates, which could further enhance spreads.

The decline in ROIC from double-digit levels to mid-single digits suggests that the $4.7B acquisition in 2026Q2 and the buildup of goodwill (now $16.5B) have not yet generated proportional earnings. While ROE remains elevated at 22.4% due to thin equity, ROIC provides a clearer picture of economic returns, which appear to be under pressure. If integration synergies materialize as management expects, ROIC could recover, but the current trend warrants close monitoring.

The negative CCC is driven by a DPO of 60 days versus DSO of 27 days and DIO of 23 days, meaning Cencora pays its suppliers after it collects from customers. This is a structural advantage of the distribution model, providing an interest-free source of funding that partially offsets the high debt load. However, the thin current ratio of 0.93 suggests that the company relies on this supplier financing and short-term debt to maintain liquidity, which could become a vulnerability if supplier terms tighten.

The extreme volatility in D/E is largely a function of thin equity, which fluctuates with retained earnings and one-off items, rather than a stable reduction in debt. Interest coverage of 8.08 in 2026Q3 is adequate but down from 14.53 in 2026Q2, and the elevated D/EBITDA of 8.44 suggests that debt service could become strained if interest rates rise or margins compress. The reliance on short-term financing for inventory procurement amplifies sensitivity to credit conditions, a key risk given the narrow net margin.

The quick ratio of 0.58 further highlights the dependence on inventory, which is less liquid, and the negative CCC suggests that the company operates with negative working capital. While this is typical for the industry and reflects the ability to collect from customers before paying suppliers, it leaves little buffer for a sudden disruption in supplier terms or a spike in inventory costs. Cash of $2.8B covers only 24% of total debt, underscoring the reliance on ongoing access to credit markets.